We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

March 19, 2021

Safeguarding digital health solutions and successful IP strategies

Commentary
Kate O'Reilly
&

To many, digital health is a relatively novel industry that has emerged at the hazy pharma-tech interface. However, as its boundaries and benefits become more apparent, investment and regulatory activity are becoming increasingly supportive, and in favour of its evolution. Unsurprisingly, these ratifications combined with the fast evolving nature of digital health and its ambition to set itself apart, has set precedence for aggressive competition within the industry. Navigating regulatory pathways and establishing reimbursement routes are hot topics among industry leaders with regard to ensuring speed-to-market and broad user reach. But we rarely hear them discuss the importance of protecting the novelty of these innovations. Is diverted focus one of the reasons why we are beginning to witness a burgeoning medtech rivalry ?

The year 2020 alone saw a number of IP-based legal battles including the long-awaited eruption between telehealth giants Teladoc and Amwell. Last autumn Teladoc filed a lawsuit against its competitor Amwell on the back of a patent infringement accusation. Teladoc claimed that Amwells products including some of its telehealth carts, a digital scope and stethoscope infringed on patents that it acquired following the acquisition of InTouch Health earlier in the year. In response, Teladoc began seeking unspecified monetary and injunctive relief under patent law. The year came to a close marked by contention between Apple and AliveCor. A lawsuit filed by AliveCor detailed that the tools included in the Apple Watch Series 4 and later devices infringed on three patents held by AliveCor, all of which focus on cardiac arrhythmia. A year prior to the unveiling of the Apple Watch's ECG, AliveCor had launched an Apple Watch strap with a built-in ECG sensor called the KardiaBand but ended sales to focus on its six-lead smartphone ECG screening device.

The evidence is rife; digital health is one of those industries destined for IP rivalry. Experts in the industry report that medical device litigation is probably the most contentious with competitor litigations going more frequently to trial than in many other industries. The solution to this is undeniable. IP protection should assume a critical component of a company’s overarching digital health strategy. But how is IP protection in digital health achieved? 

Digital health solutions can be protected from IP theft by one or more of several ways depending on the individual component of interest i.e hardware, software, associated data analytics. The channels of IP that may be used to grant such protection are myriad and include:


Trademarks and design

A carefully selected and preserved trademark is a valuable asset for digital health innovators protecting against the registration of confusingly similar marks. Engaging with an IP attorney early on is imperative to ensuring the smooth sailing of solution naming and clearance. While trademark protection is a crucial part of a company’s underlying IP strategy, it is important to remember that while it protects the name, it does not prevent competitors from copying the function of a medical device. Design rights are another important consideration that impart protection against aspects of a product's appearance; factors which are often definitive to consumer uptake and HCP adoption.


Trade Secrets

Including details such as algorithms, or manufacturing secrets in standard operating procedures (SOPs), or marketing materials can inadvertently put companies at risk of IP theft. However, trade secret protection can be achieved by educating employees on keeping information confidential and implementing programs to preserve innovation seclusion. Trade secret law often appeals more to companies as courts in general are more willing to issue injunctions under trade secret litigation in comparison to the more complex patent litigation. 


Patents

Components of digital health that may be patentable include mechanical, chemical and electrical, as well as associated methods and protocols. Protection can also be sought for user interfaces by means of utility or design patent applications. Pretty straight forward, right? But for computer-based elements, and abstract ideas things get a little bit murky. Case law developments have made it difficult for software or technology built on abstract ideas to get patent protection, and most jurisdictions require that these components can demonstrate real life outcomes. reSET®, the first FDA-approved software-only prescription digital therapeutic is one example where patent protection options wane. The software-based CBT product for substance use disorder which established efficacy in a 12-week clinical trial lists several trademarks but has no associated patents or patent applications. 


Obtaining a patent can be a long and expensive process. In the US the process involves submitting a patent application to the US Patent and Trademark Office (USPTO). Preparing the submission can take anywhere in and around the 4-8 week mark. Not so bad eh? But after the application is filed, it can take an average of 2-3 years for examination prior to the issuance of an enforceable patent. Nevertheless, patents confer several advantages for inventors in that they offer the strongest form of IP protection and allow a monopoly over an invention for a fixed period. They are often considered currency to secure financing through venture capital or private equity investments. In addition to discouraging competitors and attracting investments, patents also bolster a company’s reputation for originality in its field, which helps attract top talent. 


The top 100 Global Digital Health Patents for 2018-2020 illustrated that patenting is the still one of the most sought after channels for protecting innovation. China's Ping An topped the IP charts leading with 1,074 patent patent filings during the time period, followed closely in line by Philips (1,021 applications) and Johnson & Johnson (535 applications). So far this year we have seen continued patent activity with Voluntis receiving a patent for its intelligent insulin titration support as part of its Theraxium Digital Therapeutic Platform, and Neurosigma expanding its patent portfolio to covering the use of trigeminal nerve stimulation (TNS) in the treatment of neurological and neuropsychiatric disorders. Mydecine also made headlines last month when it filed a provisional patent for its technology combining a digital mental health programme and the world’s first telehealth platform for psychedelic integration.

Product life cycle opportunities

One reason why companies initially lean towards digital solutions is to reinforce their IP portfolios and product commercialisation strategies. Patents for pharmaceutical drugs typically confer 20 years protection but once a patent expires and generics begin to hit the market it is estimated that sales of the originator drops by a whopping 80 percent. Prior to the digital revolution, drug product developments and iterations typically involved tweaks in formulations, routes of administration, expansion of indications or development of drug-drug combinations. The inception of the digital health era  has, however, created myriad opportunities to strengthen and diversify a drug patent portfolio by means of combination product approaches, or device differentiation. One example of this is the teaming up of Otsuka and Proteus to develop Abilify MyCite®. The prescription digital medicine combines the blockbuster antipsychotic Abilify® and embedded microsensors for digitally tracking drug ingestion and has shown to improve clinical outcomes compared to Abilify® creating a novel opportunity for extending the product life cycle.

Proteus’s patents covering innovations in Abilify MyCite® expire after those of Otsuka’s for Abilify®. 


In the US, patent extension is classified under FDA (505-B) and provides pharma an opportunity and incentive for iterative product development. The Otsuka and Proteus partnership is testament to the fact that combining digital health solutions with conventional drugs can be leveraged to extend patent lifespans, allowing greater return on investment and invigorated product life cycles.


………... but what about all that data?

It goes without saying that digital health products collect an abundance of data, typically stored in designated databases. While the data itself may not be protected by copyright, the database or data collection may be protected if it is considered sufficiently avant-garde.


Building a successful digital health IP Strategy 

IP is a key driver of innovation in the digital health industry and investing in its protection will reap enormous reward and diversity of solutions in the future. One crucial consideration to bear in mind is that product life cycles in the digital health industry are typically much shorter than other healthcare industries, putting added pressure on digital health manufacturers to regularly revise and update their IP strategy. Furthermore, considering the patentable exclusion criteria which pertains to the likes of mathematical methods and algorithms, players in the digital health field rely more heavily on streams of auxiliary protection such as copyright and trade secrets.


IP has facilitated cutting-edge collaborations between the medtech, healthcare and pharmaceutical industries and nurturing an ecosystem that appropriately balances innovation with IP challenges is imperative to ensuring continued industry growth and timely access by patients to innovative healthcare solutions worldwide. Every single solution on the digital health market today is a by-product of some individual's incipient idea. How would you protect the transformation of your own ideas into assets?


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

What are the best routes to market in DTx?

12th April @ 11:00am EDT

Join us as we discuss what are the most scalable and sustainable routes to market in DTx. Great opportunity to connect with peers and meet new people.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Masterclass - The regulation of DTx

15th April @ 10:30am EDT

Join us in this Masterclass led by Stephen Gibney from BlueBridge Technologies as we discuss the regulation of DTx. Great opportunity to Listen, engage and most importantly, enjoy.

Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Why is Medtech right for DTx and vice versa

22nd April @ 11:30am EDT

Join our Digital Health Meeting as we discuss why Medtech is right for DTx and vice versa. Apply promptly to get involved in the conversation, network with peers and share your thoughts on the topic.

Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Vivian Emmely de Ruijter
Vivian Emmely de Ruijter
Senior Manager, Digital and Technology Group, Manatt Ventures at Manatt, Phelps & Phillips, LLP
Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Vivian Emmely de Ruijter
Vivian Emmely de Ruijter
Senior Manager, Digital and Technology Group, Manatt Ventures at Manatt, Phelps & Phillips, LLP
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

DTx - Overview of market and deals

28th April @ 10:30AM EDT

Join our Digital Health Meeting focused on the overview of market and deals in the DTx industry. Apply promptly to secure your place in the discussion and network with peers.

Featuring
Ethan Wergelis-Isaacson
Ethan Wergelis-Isaacson
Digital Health Strategy & Business Development , Otsuka Pharmaceutical Companies
Featuring
Ethan Wergelis-Isaacson
Ethan Wergelis-Isaacson
Digital Health Strategy & Business Development , Otsuka Pharmaceutical Companies

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

What are the best routes to market in DTx?

12th April @ 11:00am EDT

Join us as we discuss what are the most scalable and sustainable routes to market in DTx. Great opportunity to connect with peers and meet new people.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support

The future of digital medical education

13th April @ 10:30am EDT

Join us as we discuss the future of digital medical education and its impact on digital health adoption. Great opportunity to connect with peers, engage in thought-provoking conversations and meet new people.

Featuring
Joshua Landy MD
Joshua Landy MD
Chief Medical Officer, Figure 1
Meg Barron
Meg Barron
Vice President, Digital Health Strategy, American Medical Association
Featuring
Joshua Landy MD
Joshua Landy MD
Chief Medical Officer, Figure 1
Meg Barron
Meg Barron
Vice President, Digital Health Strategy, American Medical Association
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support

Role of digital patient communities in 2021

14th April @ 10:30am EDT

Join our Digital Health Meeting as we discuss the role of digital patient communities in 2021. Apply now to secure your place in the conversation and gain valuable insights from thought leaders in the industry.

Featuring
Chelsea Pan
Chelsea Pan
Partnership Engagement Manager, Verily Life Sciences
Carlos Rodarte
Carlos Rodarte
Founder & Managing Director, Volar Health LLC
Featuring
Chelsea Pan
Chelsea Pan
Partnership Engagement Manager, Verily Life Sciences
Carlos Rodarte
Carlos Rodarte
Founder & Managing Director, Volar Health LLC
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Masterclass - The regulation of DTx

15th April @ 10:30am EDT

Join us in this Masterclass led by Stephen Gibney from BlueBridge Technologies as we discuss the regulation of DTx. Great opportunity to Listen, engage and most importantly, enjoy.

Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.